2 Potential Stock Splits to Watch for in 2026
Key Points
Stock splits may not alter a company's fundamentals, but keeping an eye on stocks that are likely to experience a split could be a profitable move.
Dutch semiconductor manufacturing equipment maker ASML Holding now trades for over $1,100 per share.
Eli Lilly has reached four-digit price levels, as it experiences strong growth thanks to the success of its weight-loss drug Zepbound.
- 10 stocks we like better than Eli Lilly ›
Stock splits have zero impact on a stock's underlying value. However, these splits can make shares more accessible to a greater number of retail investors as they reduce per-share price, by increasing the number of shares overall.
That's not all. Stock splits typically occur when a stock is on a bullish trajectory. With this in mind, you may want to keep an eye on stocks with strong potential to split in the near future, such as ASML Holding (NASDAQ: ASML) and Eli Lilly (NYSE: LLY).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
After nearly two decades, ASML Holding may be ready for a stock split
It's been nearly 20 years since ASML Holding completed a stock split. However, for the Netherlands-based advanced semiconductor equipment systems manufacturer, now may be as good a time as ever to do so.
Over the past year, the company's shares have surged by over 54% as I write this, reaching prices of more than $1,100 per share. Completing a stock split would significantly increase the number of small investors who can afford to buy this AI winner without resorting to fractional shares.
Fundamentals-wise, ASML remains well positioned for further upside in 2026. Management continues to guide for growth in 2026 as strong as that in 2025. Sell-side analyst forecasts call for sales and earnings growth of 14.8% and 28.3%, respectively, this year.
Eli Lilly appears primed for a split as well
Eli Lilly hasn't had a stock split since 1997, but it may just be ready for one. Eli Lilly shares have experienced a sharp price surge and now trade above $1,000 per share, reaching a $1 trillion market cap.
Investors are bullish on the pharma giant due to the success of its weight-loss drug Zepbound. For drugs in this category, known as incretin analogs, Lilly now controls nearly 58% of the U.S. market.
Lilly sports a rich valuation, trading at a forward price-to-earnings ratio of around 27, and whether it splits or not, investors may be willing to bid it up again, as analysts anticipate earnings growth of over 35% next year.
Should you invest $1,000 in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $540,587!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,118,210!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of December 8, 2025
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ASML. The Motley Fool has a disclosure policy.
Recommended Articles
